Viewing Study NCT00689156

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:14 PM
Ignite Modification Date: 2026-01-24 @ 2:01 AM
Study NCT ID: NCT00689156
Status: COMPLETED
Last Update Posted: 2018-04-05
First Post: 2008-05-29
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer
Sponsor: Danish Breast Cancer Cooperative Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Epirubicin View
None docetaxel View
None Adjuvant chemotherapy View
None DNA Topoisomerases, Type II View